JUVÉDERM VOLUMA® to Enhance the Appearance of the Asian Nose

Inclusion criteria

• Asian subjects aged 20 years of age or older with dissatisfaction of their aesthetic appearance due to structural features of their nose
• Subjects who, in the opinion of the Investigator, can achieve a clinically meaningful aesthetic correction of their nose with VOLUMA® treatment

Exclusion criteria

• -Subjects requiring filler treatment in or around the tip of the nose or between the eyebrows (glabellar region) to achieve a good aesthetic outcome
• prior nasal surgery, including grafts, implants or filler injection to the nose area
• Subjects with a history of sinusitis or rhinitis
• Subjects unlikely to achieve a meaningful aesthetic result with the prescribed dosage regimen of the study product.
• Subjects receiving botulinum toxin treatment for any indication within 3 months of the study or planning to receive botulinum toxin during the study
• Subjects who have previously received aesthetic treatment in the forehead, glabellar, and/or nose area with any dermal filler
• Subjects with a history of any significant adverse events caused by dermal fillers
• Subjects with a history of allergic responses to lidocaine or fillers
• Subjects who are pregnant or breastfeeding or wish to become pregnant during the study
• Subjects of child-bearing age who are not prepared to practice an adequate form of contraception during the course of the study
• Subjects with traumatic scars in the treatment area or a history of active inflammation, infection, cancerous lesion, or an unhealed wound in the treatment area
• Subjects requiring dental or oral surgery, including dental implants, during the study period
• Subjects with a history of bleeding disorders
• Subjects who are smokers
• Subjects using blood thinning products within 10 days of the screening visit
• Subjects with a history of connective tissue disease (e.g., rheumatoid arthritis, lupus, scleroderma, etc) causing skin scarring
• Subjects with a history of untreated epilepsy or other significant medical conditions
• Subjects with a history of alcoholism or drug abuse of dependence
• Subjects participating or likely to participate in another clinical trial within 30 days of screening or during the 1 year period of the study
• Subjects with any other medical condition, which in the opinion of the Investigator, might compromise the subject's ability to tolerate the injection procedure or comply with requirements of the study